Nevertheless, this is the first study examining the efficacy and outcomes of ICIs administered alone and in combination with chemotherapy in patients with EGFR-mutant NSCLC in an area with a high prevalence of EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.